GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK and Microsoft, in collaboration with the Centre for Health and Disease Studies, launch disease surveillance project in Nepal

For media and investors only- Climate change is impacting the spread of known and novel pathogens, especially mosquito-borne diseases- New partnership combines expertise across Biopharm... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK launches Sustainable Procurement Programme for suppliers

For media and investors only- From 2023, the company will require and support suppliers to take action on sustainability commitments and make improvements on emissions, energy, heat, tr... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
Zejula (niraparib) shows durable and sustained long-term progression-free survival benefit in the PRIMA study of first-line platinum-responsive advanced ovarian cancer

For media and investors onlyHRd patients treated with Zejula were estimated to be more than twice as likely free of progression or death at four years as compared to placeboZejula maint... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces update on US FDA regulatory review of daprodustat in anaemia of chronic kidney disease

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) will convene a meeting of the Cardiovascular and Renal Drugs Advisory... Read More
GSK
3 years ago ⋅ English ⋅ 1 min read
Newsroom
WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine

For media and investors only- First prequalification for a malaria vaccine- Important step for rolling out the vaccine to children living in regions with moderate to high transmissionGS... Read More
GSK
3 years ago ⋅ English ⋅ 7 min read
Newsroom
GSK to highlight the latest advances in cancer research from across its portfolio and pipeline at ESMO

For media and investors onlyLong-term data presented adds further evidence to the role of Zejula in the first-line maintenance setting for advanced ovarian cancerAdditional data for Jem... Read More